Patents Issued in April 13, 2017
  • Publication number: 20170100366
    Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
    Type: Application
    Filed: December 16, 2016
    Publication date: April 13, 2017
    Inventors: Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
  • Publication number: 20170100367
    Abstract: The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.
    Type: Application
    Filed: May 27, 2015
    Publication date: April 13, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Makoto ASANO, Bruce A. LITTLEFIELD, Junji MATSUI, Martin OLIVO, Yoichi OZAWA, Yanke YU
  • Publication number: 20170100368
    Abstract: The invention features methods for treating cancer in a patient in need thereof by administering eribulin, in combination with one or more PARP inhibitors, and, optionally, a platinum-based antineoplastic drug, and kits therefor. The invention is based in part on the observation that combinations of eribulin mesylate, a PARP inhibitor (e.g., E7449), and, optionally, a platinum-based antineo-plastic drug (e.g., carboplatin), show improved (e.g., synergistic) antitumor effects. Therefore, the present invention features methods of preventing and treating cancer (e.g., homologous recombination (HR)-deficient cancer by the use of combinations of eribulin (e.g., eribulin mesylate) and one or more PARP inhibitors (e.g., E7449 or a pharmaceutically acceptable salt thereof (e.g., the tartrate salt), optionally in combination with a platinum-based antineoplastic drug (e.g., carboplatin).
    Type: Application
    Filed: May 28, 2015
    Publication date: April 13, 2017
    Inventors: David COX, Alton KREMER, Sharon MCGONIGLE, Jiayi WU
  • Publication number: 20170100369
    Abstract: Provided herein are pharmaceutical compositions, each comprising a pyrone compound, for example, a compound of Formula I, and a pharmaceutically acceptable excipient. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an inflammatory, neurodegenerative, or immune-mediated disease (e.g., multiple sclerosis).
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Inventors: Armen Manoukian, Fabrizio Mastronardi, Sam Scanga, Frank Mercurio, Kyle W.H. Chan
  • Publication number: 20170100370
    Abstract: The invention provides compositions and methods to treat a hyperproliferative disorder with ascorbate or a pharmaceutically acceptable salt thereof, at least one chelating agent that enhances ascorbate redox cycling (EDTA) to form H2O2, and one or more anti-cancer therapies.
    Type: Application
    Filed: October 12, 2016
    Publication date: April 13, 2017
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Bryan G. Allen, Douglas R. Spitz, Garry R. Buettner, Joseph Cullen, Joshua Schoenfeld, Michael Schultz, Fenghuang Zhan
  • Publication number: 20170100371
    Abstract: Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 13, 2016
    Publication date: April 13, 2017
    Inventors: Gregory R. Thatcher, Debra Tonetti, Mary Ellen Molloy, Bradley Michalsen, Zihui Qin
  • Publication number: 20170100372
    Abstract: A pharmaceutical composition and a method for preventing or treating a cardiovascular disease are provided. The pharmaceutical composition includes a BIO compound ((2?Z,3?E)-6-bromoindirubin-3?-oxime) or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition can specifically act on different types of cells constituting heart tissues, that is, can induce the growth of cardiomyocytes, and can also inhibit proliferation of cardiac fibroblasts and strongly suppress inflammatory mediators in macrophages, thereby significantly recovering the tissues and functions of the heart after the onset of myocardial infarction. Therefore, the pharmaceutical composition can be effectively used to treat various cardiovascular diseases including myocardial infarction.
    Type: Application
    Filed: July 29, 2016
    Publication date: April 13, 2017
    Applicant: CHONNAM NATIONAL UNIVERSITY HOSPITAL
    Inventors: Youngkeun AHN, Yong Sook KIM, Hye-yun JEONG, Darren R. WILLIAMS, Da-Woon JUNG
  • Publication number: 20170100373
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: December 22, 2016
    Publication date: April 13, 2017
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Publication number: 20170100374
    Abstract: A combination therapy including a modulator of the function (potentiator) of cystic fibrosis transmembrane conductance regulator (CFTR) protein, and one or two modulator(s) of the cellular processing and/or localization molecule (correctors) is provided in a method for treating cystic fibrosis in a subject having a mutation located between the amino acid residues 1164-1480 of full length wild-type CFTR.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Inventors: Katja E. Conrath, Steven M. Rowe
  • Publication number: 20170100375
    Abstract: The present invention presents 2-(acylamino)imidazoles with therapeutic activity, including selective activity against cancer cells, and compositions comprising them. Methods of using and preparing the 2-(acylamino)imidazoles are also presented.
    Type: Application
    Filed: September 16, 2016
    Publication date: April 13, 2017
    Inventors: Ryan E. Looper, Rachel M. Vaden, Joseph B. Gibbons, Justin M. Salvant, Anne V. Edwards, Matthew S. Sigman, Bryan E. Welm
  • Publication number: 20170100376
    Abstract: In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable or oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.
    Type: Application
    Filed: October 12, 2016
    Publication date: April 13, 2017
    Applicant: Astellas Deutschland GmbH
    Inventors: Jeffrey Colledge, Thomas Alfred Profitlich, Ulrich Patzak, Taoufik Quatas, Margaretha Olthoff
  • Publication number: 20170100377
    Abstract: A solid oral pharmaceutical composition for delivery of a pharmaceutically acceptable active ingredient to an animal where the composition comprises an isoxazoline compound, a solvent and an excipient, a process for the manufacture of such solid oral pharmaceutical composition and a method of controlling a parasite infection administering such solid oral pharmaceutical composition.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Applicant: Intervet Inc.
    Inventors: Keith Freehauf, Niki Waldron, Jürgen Lutz, Frank Guerino
  • Publication number: 20170100378
    Abstract: The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.
    Type: Application
    Filed: June 9, 2015
    Publication date: April 13, 2017
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DA LA RECHERCHE MÉDICALE)
    Inventor: Olivier HERMINE
  • Publication number: 20170100379
    Abstract: The present invention relates to novel ?-lactam compounds, their preparation and use. In particular, this invention relates to novel ?-lactam compounds which are amidine substituted monobactam derivatives useful as antimicrobial agents and their preparation.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 13, 2017
    Applicant: AiCuris GmbH & Co. KG
    Inventors: Burkhard KLENKE, Irith WIEGAND, Guido SCHIFFER, Heike BROETZ-OESTERHELT, Samarendra N. MAITI, Jehangir KHAN, Andhe REDDY, Zhixiang YANG, Mostafa HENA, Guofeng JIA, Ou LIGONG, Hong LIANG, Judy YIP, Chuanjun GAO, Sabiha TAJAMMUL, Rahim MOHAMMAD, Ganguli BISWAJEET
  • Publication number: 20170100380
    Abstract: A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.
    Type: Application
    Filed: December 20, 2016
    Publication date: April 13, 2017
    Inventors: Gakuji Kiyonaka, Yoshihiro Furuya, Yusuke Suzuki
  • Publication number: 20170100381
    Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.
    Type: Application
    Filed: December 22, 2016
    Publication date: April 13, 2017
    Inventors: Williamson Z. Bradford, Javier Szwarcberg
  • Publication number: 20170100382
    Abstract: Provided herein are hydroxypyridone derivatives, for example, a compound of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods for treating, preventing, or ameliorating one or more symptoms of an inflammatory, neurodegenerative, or immune-mediated disease (e.g., multiple sclerosis).
    Type: Application
    Filed: December 22, 2016
    Publication date: April 13, 2017
    Inventors: Armen Manoukian, Fabrizio Mastronardi, Sam Scanga, Frank Mercurio, Kyle W.H. Chan
  • Publication number: 20170100383
    Abstract: A topical formulation comprising a first active agent that is pharmaceutically acceptable salt of a cationic bisbiguanide such as chlorhexidine digluconate (CHG), a secnd active agent which is a cationic quaternary ammonium compound such as cetylpyridinium chloride (CPC), methylisothiazolone, or chloroxylenol, and a propellant; and an aerosol dispenser containing the topical formulation. The topical formulation can be sprayed onto exposed skin to prevent or reduce the risk of skin infection.
    Type: Application
    Filed: October 12, 2016
    Publication date: April 13, 2017
    Applicant: Practical Solution, Inc.
    Inventors: Zhou WAN, Steve GLASSEY, Jay MURPHY, Wei XU
  • Publication number: 20170100384
    Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: December 22, 2016
    Publication date: April 13, 2017
    Inventors: Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
  • Publication number: 20170100385
    Abstract: Provided are compounds and pharmaceutically acceptable salts thereof, and combinations of compounds, their pharmaceutical compositions, their methods of preparation, and methods for their use in treating or preventing infectious disease.
    Type: Application
    Filed: May 8, 2015
    Publication date: April 13, 2017
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventor: Michael WASHBURN
  • Publication number: 20170100386
    Abstract: A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Inventors: Rhalid Akkari, Luke Jonathan Alvey, Xavier Marie Bock, Brian S. Brown, Pieter Isabelle Roger Claes, Marlon D. Cowart, Katja E. Conrath, Douglas Cyr, Elsa De Lemos, Gert Jules Hector De Wilde, Nicolas Desroy, Béranger Duthion, Gregory A. Gfesser, Romain Luc Marie Gosmini, Christopher Gaëtan Housseman, Koen Karel Jansen, Jianguo Ji, Philip R. Kym, Jean-Michel Lefrancois, Oscar Mammoliti, Christel Jeanne Marie Menet, Nuria Merayo Merayo, Gregory John Robert Newsome, Adeline Marie Elise Palisse, Sachin V. Patel, Mathieu Rafaël Pizzonero, Anurupa Shrestha, Elizabeth C. Swift, Chris Tse, Steven Emiel Van der Plas, Xueqing Wang
  • Publication number: 20170100387
    Abstract: The present invention provides compositions and methods for treating or preventing atrial fibrillation (AF). In particular, the present invention provides administration of muscarinic receptor antagonists (e.g., M2-selective muscarinic receptor blockers), administered alone or in combination with other therapeutic agents (e.g., beta-adrenergic receptor blockers) to treat and/or prevent atrial fibrillation.
    Type: Application
    Filed: October 25, 2016
    Publication date: April 13, 2017
    Inventors: Rishi Arora, David E. Zembower
  • Publication number: 20170100388
    Abstract: The subject invention provides methods of treating or delaying disease progression in a subject afflicted with Huntington's disease (HD) comprising administering to the subject 0.5-1.5 mg/day laquinimod. The subject invention also provides packages, therapeutic packages and pharmaceutical compositions, comprising one or more unit doses of 0.5-1.5 mg laquinimod for treating or delaying disease progression in a subject afflicted with HD. Also disclosed is use of laquinimod in the manufacture of a medicament comprising one or more unit doses of 0.5-1.5 mg laquinimod for use in treating or delaying disease progression in a subject afflicted HD.
    Type: Application
    Filed: December 22, 2016
    Publication date: April 13, 2017
    Applicant: Teva Pharmaceutical Industries, Ltd.
    Inventors: Anna Kristina Sveinsdotter Teige Wickenberg, Esther Lukasiewicz Hagai, Eli Eyal, Sigal Melamed-Gal
  • Publication number: 20170100389
    Abstract: Tetrahydroprotoberbine (THPB) compounds and their use in the treatment of neurological, psychiatric and neurodegenerative diseases is provided. The compounds include d-govadine, l-govadine and racemic govadine, as well as d-THPBs of general formula (I). Enantioselective processes for preparing compounds of formula (I), and d- and l-govadine are also provided.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Inventors: James Jackson Miller, Anthony George Phillips, Christopher Court Lapish, Glenn Martin Sammis
  • Publication number: 20170100390
    Abstract: The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.
    Type: Application
    Filed: October 3, 2016
    Publication date: April 13, 2017
    Inventor: Thomas E. Jenkins
  • Publication number: 20170100391
    Abstract: A stable liquid composition in a clear bottle where the composition contains, at least, phenylephrine and acetaminophen. The composition is substantially free of aldehydes and has a pH from 3.5 to 5. The clear bottle is a polyethylene terphthalate bottle.
    Type: Application
    Filed: December 20, 2016
    Publication date: April 13, 2017
    Inventors: Kelly Lee Martin, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines, Thomas Edward Huetter, Radhika R. Iyer, Daren K. Anness
  • Publication number: 20170100392
    Abstract: The invention relates to the use of fibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.
    Type: Application
    Filed: September 20, 2016
    Publication date: April 13, 2017
    Inventors: Franco Borsini, Kenneth Robert Evans
  • Publication number: 20170100393
    Abstract: Compositions, packaged pharmaceuticals, and methods of treatment by the sensitization of resistant tumors are provided. The compositions comprise a combination of a hedgehog pathway modulator, such as itraconazole, and a chemotherapeutic agent. Tumor cells in mammalian subjects treated with the hedgehog pathway modulator are sensitized to the effects of the chemotherapeutic agent, thus increasing the therapeutic index of the agent and reducing toxicity to the subject.
    Type: Application
    Filed: October 12, 2016
    Publication date: April 13, 2017
    Inventor: Vikash J. BHAGWANDIN
  • Publication number: 20170100394
    Abstract: The present invention relates to novel anthelmintic compounds of formula (I) below: wherein Y and Z are independently a bicyclic carbocyclic or a bicyclic heterocyclic group, or one of Y or Z is a bicyclic carbocyclic or a bicyclic heterocyclic group and the other of Y or Z is alkyl, alkenyl, alkynyl, cycloalkyl, phenyl, heterocyclyl or heteroaryl, and variables X1, X6, X8, Q1, Q2, Q3, Q4, Q5, Q6, Ring A, Ring B, W, W?, R2, R3, R, R?, m, n and q are as defined herein. The invention also provides for veterinary compositions comprising the anthelmintic compounds of the invention, and their uses for the treatment and prevention of parasitic infections in animals.
    Type: Application
    Filed: May 19, 2015
    Publication date: April 13, 2017
    Applicant: MERIAL INC.
    Inventors: Alan Long, Srinivas Reddy Gurrala
  • Publication number: 20170100395
    Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tsuyoshi HIROSE, Kenji MAEDA, Tetsuro KIKUCHI, Masafumi TODA
  • Publication number: 20170100396
    Abstract: The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, codrug, cocrystal, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameliorating or preventing influenza. Furthermore, specific combination therapies are disclosed.
    Type: Application
    Filed: October 5, 2016
    Publication date: April 13, 2017
    Inventors: Tanja SCHULZ-GASCH, Robert WEIKERT, Werner NEIDHART, Andrea WOLKERSTORFER, Oliver SZOLAR, Norbert HANDLER, Helmut BUSCHMANN, Stephen CUSACK
  • Publication number: 20170100397
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Application
    Filed: July 27, 2016
    Publication date: April 13, 2017
    Inventors: Juswinder Singh, Russell C. Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Publication number: 20170100398
    Abstract: The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 13, 2017
    Inventor: Paul Stoffels
  • Publication number: 20170100399
    Abstract: The present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors.
    Type: Application
    Filed: December 23, 2016
    Publication date: April 13, 2017
    Inventors: Jens Marcel Van Roey, Marie-Pierre T.M.M.G. De Bethune, Paul Stoffels
  • Publication number: 20170100400
    Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    Type: Application
    Filed: October 21, 2016
    Publication date: April 13, 2017
    Inventors: Paul S. Charifson, Michael P. Clark, Upul K. Bandarage, Randy S. Bethiel, John J. Court, Hongbo Deng, Ioana Davies, John P. Duffy, Luc J. Farmer, Huai Gao, Wenxin Gu, Dylan H. Jacobs, Joseph M. Kennedy, Mark W. Ledeboer, Brian Ledford, Francois Maltais, Emanuele Perola, Tiansheng Wang, M. Woods Wannamaker, Randal Byrn, Yi Zhou, Chao Lin, Min Jiang, Steven Jones, Ursula A. Germann, Francesco G. Salituro, Ann Dak-Yee Kwong
  • Publication number: 20170100401
    Abstract: Embodiments of the invention find application in the field of cancer therapy. Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets.
    Type: Application
    Filed: October 7, 2015
    Publication date: April 13, 2017
    Inventors: Xianhui Wang, Douglas S. Conklin
  • Publication number: 20170100402
    Abstract: The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of Her2, and the use of such combinations for the treatment of cancer.
    Type: Application
    Filed: March 9, 2015
    Publication date: April 13, 2017
    Inventors: Bayard R. HUCK, Erik WILKER, Andreas MACHL, Remigiusz KALETA
  • Publication number: 20170100403
    Abstract: The present application provides pharmaceutical compositions derived from pemetrexed dipotassium Nonahydrate and its process thereof. The present application also provides a method of treating cancer by administering intravenously the reconstituted lyophilized compositions into a patient in need thereof.
    Type: Application
    Filed: June 23, 2015
    Publication date: April 13, 2017
    Applicant: SHILPA MEDICARE LIMITED
    Inventors: PRADEEP SHIVAKUMAR, AKSHAY KANT CHATURVEDI
  • Publication number: 20170100404
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Inventors: Norbert Purro, Mark Stephen Smyth, Erick Goldman, David D. Wirth
  • Publication number: 20170100405
    Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Publication number: 20170100406
    Abstract: The invention relates to a combination of a FGFR inhibitor and an IGF1R inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for the treatment of cancer. The FGFR inhibitor and the IGFR inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.
    Type: Application
    Filed: March 26, 2015
    Publication date: April 13, 2017
    Applicant: ASTEX THERAPEUTICS LTD
    Inventors: Eleonora JOVCHEVA, Timothy Pietro Suren PERERA
  • Publication number: 20170100407
    Abstract: A composition comprising: hydrolysable taurolidine; and a hydrolysable lipophilic excipient; wherein the hydrolysable taurolidine is contained within the hydrolysable lipophilic excipient.
    Type: Application
    Filed: October 7, 2016
    Publication date: April 13, 2017
    Inventors: Bruce Reidenberg, Robert DiLuccio
  • Publication number: 20170100408
    Abstract: The subject-matter of the present invention is a novel, non-salified ivabradine solid form, in particular an ivabradine form adsorbed on an inert carrier. The subject-matter of the invention is also a process for preparing said solid form, its use in therapy and pharmaceutical compositions comprising it.
    Type: Application
    Filed: March 24, 2015
    Publication date: April 13, 2017
    Inventors: Giorgio BERTOLINI, Cinzia BIAGGI, Ilaria FERRANDO
  • Publication number: 20170100409
    Abstract: Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (S)-(?)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, KOWA COMPANY, LTD.
    Inventors: Tatsuro Ishibashi, Shintaro Nakao, Ryoichi Arita, Ken Mizuno, Akifumi Tsuchiura
  • Publication number: 20170100410
    Abstract: Provided are methods for treatment and prevention of ischemia-reperfusion injury and chronic intermittent hypoxia related injury through administering a neuroprotective compound. A subject benefiting from the method of the invention may be prescribed or undergoing anti-VEGF treatment, for example an IVAV treatment regimen, or may be diagnosed with a disorder such as sleep apnea.
    Type: Application
    Filed: June 27, 2016
    Publication date: April 13, 2017
    Inventor: Tamara Vrabec
  • Publication number: 20170100411
    Abstract: This invention relates to compositions and methods for achieving and maintaining maximal analgesic effect following intra-articular administration of corticosteroid formulations. The invention also describes extended release, e.g., controlled- or sustained-release corticosteroid formulations, including extended release, e.g., controlled- or sustained-release formulations of triamcinolone acetonide (TCA), fluticasone propionate, cortisol, ciclesonide (monopropionate), beclometasone diproprionate, dexamethasone, flunisolide, budesonide, desisobutyryl-ciclesonide, and/or mometasone furoate, that produce a maximal analgesic effect greater than the acute analgesic effect provided by standard corticosteroid suspensions, including non-extended release corticosteroid suspensions, and that are also associated with a clinically insignificant effect on endogenous cortisol production following administration, for example, intra-articular, intrathecal, epidural, intra-bursal, or other local administration.
    Type: Application
    Filed: October 13, 2016
    Publication date: April 13, 2017
    Inventors: Neil Bodick, Derek Jackson, Toni Williamson
  • Publication number: 20170100412
    Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
    Type: Application
    Filed: June 30, 2016
    Publication date: April 13, 2017
    Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
  • Publication number: 20170100413
    Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more analgesic agents and a PDE5 inhibitor. Also disclosed are methods of making and using of the pharmaceutical compositions.
    Type: Application
    Filed: December 9, 2016
    Publication date: April 13, 2017
    Inventor: David A. DILL
  • Publication number: 20170100414
    Abstract: Small molecule efflux pump inhibitors are provided, as well as methods for their use in treating infections. Also provided herein are methods of using the small molecule efflux pump inhibitors to restore the antibiotic susceptibility of microbes.
    Type: Application
    Filed: June 12, 2015
    Publication date: April 13, 2017
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Paul M. Dunman, Catlyn E. Blanchard
  • Publication number: 20170100415
    Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.
    Type: Application
    Filed: October 27, 2016
    Publication date: April 13, 2017
    Inventors: Yoram RICHTER, Elazer R. EDELMAN, Gershon GOLOMB, Haim D. DANENBERG